Recovery and muscle claims
Read recovery claims with the product name in view
If the pitch is about recovery or muscle, ask for evidence about the exact product and the exact use. Keep a confident claim from standing in for an answer.
What the US record establishes
The September 2026 review found no US approved product for BPC-157, ipamorelin, epitalon or MOTS-c.
Finding no approved product does not, by itself, tell you whether the drug causes harm or whether a pharmacy may legally make it.
The FDA’s September 2026 record notes possible immune reactions and unwanted material mixed in with some peptides. An immune reaction here means your body responds to the peptide as something foreign. For some peptides, too little human safety data exists to tell what harm they might cause.
A withdrawn request is not clearance
People or groups had asked the FDA to allow pharmacies to use BPC-157, CJC-1295 and TB-500 as ingredients, then took those requests back. The FDA page dated April 22, 2026 lists those withdrawn requests and still gives its safety concerns beside the names.
As checked in September 2026, withdrawing a request gave no approval and no new permission to make a medicine from that ingredient. These peptides did not join the FDA group for which it says it will hold off taking action against a pharmacy.
That temporary promise to hold off applies only if the pharmacy meets the conditions in FDA guidance; it is not a ruling that making the drug is lawful.